Appearing as a noteworthy advance in the struggle against obesity, the drug is attracting considerable attention . This treatment combines the action of two established GLP-1 receptor agonists, dulaglutide , and an unique glucose-dependent incretin component. Initial patient data have indicated impressive fat loss in people with obesity , possibly